Skip to main content
AIDX
NASDAQ Industrial Applications And Services

CEO Jonathan Cohen Discloses 16.8% Stake in 20/20 Biolabs, Including Recent Option Grants

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$2.91
Mkt Cap
$13.768M
52W Low
$2.51
52W High
$50
52W Position info
16% above low
Off High info
94% below high
Rel. Volume info
1.5× avg
Market data snapshot near publication time

AIDX sits 16% above its 52-week low of $2.51.

Summary

CEO Jonathan Cohen has filed an initial Schedule 13D, disclosing a beneficial ownership of 16.8% of 20/20 Biolabs, Inc.'s common stock, primarily through shares acquired for services and vested stock options.


Key Events · Ownership and Investor Activity · AIDX

  • CEO Discloses Significant Stake

    Jonathan Cohen, CEO of 20/20 Biolabs, Inc., has filed an initial Schedule 13D, reporting beneficial ownership of 1,833,750 shares, representing 16.8% of the company's outstanding common stock.

  • Shares Acquired for Services and Options

    The reported stake includes 1,366,400 shares received for services in 2000 and 467,350 shares exercisable within 60 days from vested stock options, with the latest option grant on March 3, 2026.

  • No Immediate Plans for Corporate Changes

    The filing states that the Reporting Person has no current plans or proposals that would result in major corporate events or changes to the company's structure or business.


Analysis · AIDX · Industrial Applications And Services

This initial Schedule 13D filing reveals that CEO Jonathan Cohen holds a substantial 16.8% stake in 20/20 Biolabs, Inc. Such a significant ownership percentage by a chief executive officer typically signals strong alignment with shareholder interests and confidence in the company's long-term prospects. The stake includes shares received for services and a substantial portion of vested stock options, with the most recent option grant occurring on March 3, 2026. While the filing does not indicate any immediate plans for corporate changes, the disclosure of such a concentrated insider holding is a key indicator for investors.

At the time of this filing, AIDX was trading at $2.91 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $13.8M. The 52-week trading range was $2.51 to $50.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AIDX - Latest Insights

AIDX
Jul 09, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.6098
Real-time Price: $0.5292 info
Change: -$0.0806 (-13%) info
Market Cap: $6.483M info
AIDX
Jul 01, 2026, 3:28 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.61565
Real-time Price: $0.5292 info
Change: -$0.08645 (-14%) info
Market Cap: $6.483M info
AIDX
Jun 23, 2026, 5:02 PM EDT
Filing Type: DEF 14A
Importance Score:
9
Price at Filing: $0.6022
Real-time Price: $0.5292 info
Change: -$0.073 (-12%) info
Market Cap: $6.483M info
AIDX
Jun 01, 2026, 4:40 PM EDT
Filing Type: PRE 14A
Importance Score:
9
Price at Filing: $1.01
Real-time Price: $0.5292 info
Change: -$0.4808 (-48%) info
Market Cap: $6.483M info
AIDX
May 26, 2026, 4:28 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.03
Real-time Price: $0.5292 info
Change: -$0.5008 (-49%) info
Market Cap: $6.483M info